Radioligand therapy for HER2-positive cancers enters human trials for the first time. The McGill University Health Centre (MUHC) is the first site in the world to launch a first-in-human phase 1 clinical trial evaluating a novel radioligand therapy for HER2-positive cancers, including certain types of breast cancer.
A apuração publicada por medicalxpress.com vira base para uma leitura editorial direta e contextualizada.
Trechos de apoio da pauta: The McGill University Health Centre (MUHC) is the first site in the world to launch a first-in-human phase 1 clinical trial evaluating a novel radioligand therapy for HER2-positive cancers, including certain types of breast cancer.
- Ponto de atenção: radioligand.
- Ponto de atenção: therapy.
- Ponto de atenção: her2.
Em resumo, a leitura editorial acompanha o impacto do tema no nicho Fitness.
